Boardroom Alpha
Boardroom Alpha
NMRA · Additional Proxy Materials (DEFA14A) · Filed April 17, 2026

Neumora Therapeutics Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 17, 2026
Ticker
NMRA
Accession
0001193125-26-161519
Boardroom Alpha · Filing insights

Neumora Therapeutics' DEFA14A covers the 2026 annual meeting: elect three Class III directors, ratify EY, and advisory exec-compensation votes.

About Neumora Therapeutics Inc
Market cap
$324M
1Y TSR
+132.9%
Board grade
D
Sector
Healthcare
CEO
Paul L Berns
Last annual meeting: May 27, 2026 · View full Neumora Therapeutics Inc profile →
DEFA14A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

(Amendment No. )

 

Filed by the Registrant ☒

Filed by a party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

NEUMORA THERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 


 

img13113273_0.jpg

 

Your vote counts Numora Therapeutics, Inc. 2026 Annual Meeting vote by May 26, 2026 11:59 PM ET. Neumora Therapeutics, INC. 460 Arsenal Street, Suite 1 Watertown, MA 024732 V94606-P52588 you invested in neumora therapeutic’s, Inc. and its time to vote! You have the right to vote on proposals being presented at the annual meeting. This is an notice regarding the availability of proxy materials for the stockholder meeting to be held on Monday 27, 2026. Get informed before you vote. View the Notice and Proxy Statement and 10-K online or you can receive a free paper or email copy of the material(s) by requesting prior to may 13, 2026. If you would you like to request a copy of the material (s) for this and/or future stockholder meeting, you may (1) visit www.proxyvote.com, (2) call 1-800-579-1369 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and vote, visit www.proxyvote.com control # smartphone users point your camera here and vote without entering a control number. Vote virtually at the meeting* May 27, 2026 4:00 PM EDT. *Please check the meeting materials for any special requirements for meeting attendance.

 

 


 

img13113273_1.jpg

 

Vote at www.proxyvote.com. This is not a votable Ballot. This is an overview of the proposal being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting items 1. To elect three Class III directors to hold until the 2029 annual meeting of stockholder or until their successors are elected: Nominees 1a. Paul Berns For 1b. Matthew Fust For 1c. David Piacquad For 2. To ratify the appointment, by the Audit Committee of the company’s Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm and independent auditor of the company for the year ending December 31, 2026. For. 3. Advisory Vote on the compensation of our named executive officers. For. 4. Advisory vote on the frequency of future advisory on the compensation of our named executive officers. Year Board Recommends prefer to receive an email instead? While voting on www.Proxy vote.com, be sure to click “Delivery Settings”.

 


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Neumora Therapeutics Inc (NMRA)

Reference

Frequently asked questions

When did Neumora Therapeutics Inc file this DEFA14A?
Neumora Therapeutics Inc (NMRA) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 17, 2026. The accession number assigned by EDGAR is 0001193125-26-161519.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Neumora Therapeutics' DEFA14A covers the 2026 annual meeting: elect three Class III directors, ratify EY, and advisory exec-compensation votes. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Neumora Therapeutics Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Neumora Therapeutics Inc has filed under CIK 1885522, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer